Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06532071 · ClinicalTrials.gov registry record · Phase 2
Advanced Imaging for Pulmonary Fibrosis
A Phase 2 study of Pulmonary Fibrosis, sponsored by Peter Caravan.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06532071: Recruiting Phase 2 study of Pulmonary Fibrosis, sponsored by Peter Caravan.
NCT06532071 is a Phase 2 study of Pulmonary Fibrosis that is actively recruiting participants, run by Peter Caravan. The registered enrollment target is 60 participants, below the 886-participant average among 22 other Pulmonary Fibrosis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06532071, a Phase 2 study of Pulmonary Fibrosis, is actively recruiting participants, sponsored by Peter Caravan.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can predict an individual patient's pace of disease progression in non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD) and identify which individuals will develop progressive pulmonary fibrosis.
Primary Outcome
Defined by the 2022 ATS guideline definition of progressive pulmonary fibrosis (PPF) which defines PPF as satisfying 2 of 3 criteria within 12 months: worsening symptoms, physiologic progression (absolute decline in FVC ≥ 5% or absolute decline in DLCO ≥ 10%), or radiologic evidence of disease progression.
Conditions Studied
Interventions
- DRUG [68Ga]CBP8
- DRUG Gadoterate Meglumine
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-01-21 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
What NCT06532071 shows while recruiting
NCT06532071 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 886-participant average among 22 other Pulmonary Fibrosis trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which [68Ga]CBP8 is the first listed.
NCT06532071 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06532071 about?
NCT06532071 is a clinical study titled "Advanced Imaging for Pulmonary Fibrosis". The purpose of this study is to determine if measurements of active collagen deposition using \[68Ga\]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can predict an individual patient's pace of disease progression in non-...
What is the current status of trial NCT06532071?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2025-01-21. Estimated completion is 2028-12-31.
What conditions does trial NCT06532071 study?
This clinical trial studies the following conditions: Pulmonary Fibrosis.
What interventions are being tested in trial NCT06532071?
The interventions under investigation include: [68Ga]CBP8 (DRUG), Gadoterate Meglumine (DRUG).
Who is sponsoring clinical trial NCT06532071?
This trial is sponsored by Peter Caravan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06532071 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06532071's enrollment target sits among peer trials
60 15th of 22 higher than 7 of 22 other Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis
ACTIVE NOT RECRUITING · Phase 2
-
Pulmonary Fibrosis Foundation Community Registry
RECRUITING
-
Interstitial Lung Disease Research Unit Biobank
RECRUITING
-
FAPI PET for Lung Fibrosis
RECRUITING · Early Phase 1
-
Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis
RECRUITING
-
Telehealth and Onsite Maintenance Exercise in Chronic Lung Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI